Cyclosporine (Atopica) for Canine Atopic Dermatitis: Evidence and Use

Bottom line

• Cyclosporine (Atopica/Atopica for Dogs) is FDA-approved under NADA 141-218 for control of atopic dermatitis in dogs and acts via T-cell immunosuppression and inhibition of interleukin-2. [1]
• In the pivotal US/Canada multisite placebo-controlled field study (n=265), CADESI lesion scores improved 45% from enrollment at 30 days versus a 9% worsening in the placebo group; 74% of cyclosporine-treated dogs showed pruritus improvement vs 24% of placebo-treated dogs (p<0.0001). [1]
• Onset of pruritus reduction takes approximately 4 weeks when cyclosporine is used as monotherapy; adding a short course of prednisolone at initiation accelerates pruritus reduction to within days 3-4. [2]
• Most common adverse reactions are vomiting (30.9%) and diarrhoea (20.0%); these typically resolve spontaneously with continued dosing. [1]
• Cyclosporine is a systemic immunosuppressant; long-term use requires monitoring and is contraindicated in dogs with a history of neoplasia. [1]

Drug facts

• Class: Cyclic polypeptide immunomodulator; calcineurin inhibitor
• Mechanism: Suppresses T-helper and T-suppressor lymphocytes; inhibits interleukin-2; does not depress haematopoiesis or phagocytic cell function
• Route/interval: Oral; initial daily dosing per the label; may taper to every other day or twice weekly as response permits
• Indication: Control of atopic dermatitis in dogs (FDA NADA 141-218) [1]
• Approval: FDA NADA 141-218 (Elanco US Inc., marketed as Atopica); first marketed November 2015 under current labelling
• Label contraindications: History of neoplasia; hypersensitivity to cyclosporine [1]
• Label common AEs: Vomiting (30.9%), diarrhoea (20.0%), persistent otitis externa (6.8%), urinary tract infection (3.8%), anorexia (3.0%), lethargy (2.3%), gingival hyperplasia (2.3%); papillomatous skin lesions at higher-than-recommended doses in safety studies [1]

A specific patient on cyclosporine?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=cyclosporine-canine-atopic-dermatitis

What the evidence shows

Pivotal field study: FDA approval basis (Atopica DailyMed label)

The core efficacy evidence for the FDA label consisted of a multisite, placebo-controlled, double-masked field study conducted at 16 investigator sites in the United States and Canada enrolling 265 dogs aged 1-10 years. Dogs were randomised to Atopica capsules at the label dose per the label or placebo for 30 days, after which placebo dogs were crossed over to Atopica for the remainder of the 4-month study.

At the end of the 30-day placebo-controlled period, CADESI scores for the cyclosporine group improved 45% from enrollment while placebo scores worsened 9%. Owner and Veterinary Global Assessment scores in the cyclosporine group showed approximately twice as much improvement as placebo at 4 weeks (p<0.0001 for both). Seventy-four percent of cyclosporine-treated dogs showed improvement in pruritus scores over the first 30 days compared with 24% of placebo dogs. Analysis of blood cyclosporine levels demonstrated no correlation with CADESI scores or pruritus outcomes, indicating that therapeutic drug monitoring is not indicated for efficacy monitoring. [1]

Accelerating onset with concurrent prednisolone (Dip et al. 2013)

A recognised clinical challenge with cyclosporine monotherapy is the approximately 4-week lag to maximal pruritus reduction, which affects owner adherence and quality of life. Dip and colleagues conducted a randomised multicentre trial (n=48, 5 US and 5 French dermatology referral centres) comparing cyclosporine A at the label-recommended dose once daily alone (n=25) against the same cyclosporine regimen with concurrent prednisolone per the Dip et al. 2013 protocol for the first 20 days (n=23) for atopic dermatitis in dogs.

Owner-assessed pruritus VAS showed a significant reduction as early as days 3-4 in the combination group (p=0.0001, mean reduction 36.3%) versus days 7-8 in the cyclosporine-alone group (p=0.0022, mean reduction 13.0%). By day 14, the combination group had achieved an average 72.8% pruritus reduction compared with 24.6% for cyclosporine alone. By day 28, the two groups converged, with 65.1% and 42.4% reductions respectively (not significant, p>0.025).

CADESI-03 lesion scores were significantly lower in both groups at days 14 and 28 compared with baseline, with no statistically significant difference between groups at either visit point. No dogs died or discontinued treatment due to adverse events. Vomiting was more common in the cyclosporine-alone group (13 events in 10 dogs vs 2 events in 2 dogs); lethargy was more common in the concurrent prednisolone group (4 cases, resolving within 3-8 days after prednisolone stopped). All adverse events were consistent with established profiles for the individual drugs. [2]

Mechanism and drug interactions

Cyclosporine is extensively metabolised by cytochrome P-450 enzymes in the liver and to a lesser degree in the gastrointestinal tract and kidney. Drugs that inhibit P-450 (e.g. azole antifungals such as ketoconazole, itraconazole) can substantially increase plasma cyclosporine concentrations; this interaction is clinically relevant when treating concurrent fungal infections in atopic dogs. Conversely, inducers of P-450 (e.g. phenobarbital) may reduce cyclosporine levels. [1]

Dosing and long-term management

The initial label dose is a single daily dose for 30 days per the label. Following this induction period, the dose frequency may be reduced to every other day or twice weekly to the minimum effective frequency. Not all dogs achieve the lowest frequency; those unable to decrease from once-daily dosing after 60 days are considered frequency-reduction failures. Cyclosporine should be given at least one hour before or two hours after a meal, as food reduces bioavailability. [1]

How this fits clinical practice

Cyclosporine remains a well-established first-line systemic option for canine atopic dermatitis. The 4-week onset of full pruritus control is the primary limitation in managing owner expectations; the concurrent-prednisolone initiation strategy — used for a maximum of approximately 20 days — substantially closes this gap without evidence of additional immunosuppression risk at the low short-term prednisolone doses studied. The key risks with long-term cyclosporine use are opportunistic infections, gingival hyperplasia, and the precautionary contraindication in dogs with known or suspected neoplasia. Regular clinical monitoring is recommended; therapeutic drug monitoring of blood levels is not supported by the evidence as a tool for efficacy prediction.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=cyclosporine-canine-atopic-dermatitis

References

1. Elanco US Inc. Atopica (cyclosporine capsules USP MODIFIED). DailyMed NADA 141-218. Revised November 2025. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=99642708-0a9f-4ff0-bc08-f2b18691927e
2. Dip R, Carmichael J, Letellier I, et al. Concurrent short-term use of prednisolone with cyclosporine A accelerates pruritus reduction and improvement in clinical scoring in dogs with atopic dermatitis. BMC Vet Res. 2013;9:173. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847128/

Changelog

• 2026-06-07: First published.